nach oben

Erschienen in:

04.11.2022 | COVID-19 | Review articles

Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions

verfasst von: Antonio Vitiello, MD, Andrea Zovi, PD, Ugo Trama, MD, Francesco Ferrara, MD

Erschienen in: Herz | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) triggered the pandemic of COVID-19, which is currently still ongoing. In 2021 a worldwide vaccine campaign was launched, and in parallel the lines of research are continuing to target the most effective drug therapies for the treatment of COVID-19 disease. SARS-CoV‑2 enters host cells via glycoprotein angiotensin-converting enzyme 2 (ACE-2), which plays a major role in renin–angiotensin system interactions and undergoes changes in expression during metabolic and viral diseases, including COVID-19. It seems that the severe lung damage that occurs in several cases of COVID-19 disease may be connected to a deregulated expression of ACE‑2. In this manuscript we focus on the line of research that studies the pharmacological modification of ACE‑2 expression, a promising weapon to counter the severe harms caused by COVID-19.

World health organization (WHO) (2022) Situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed September 2022

Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470–473CrossRefPubMedPubMedCentral

Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506CrossRefPubMedPubMedCentral

Vitiello A, Porta R, Pianesi L, Ferrara F (2021) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https://doi.org/10.1007/s11845-021-02584-5CrossRefPubMedPubMedCentral

Li Q et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207CrossRefPubMedPubMedCentral

Zhu N et al (2019) A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(2020):727–733

Gorbalenya AE et al (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus study group. Microbiology. https://doi.org/10.1101/2020.02.07.937862CrossRef

Guarner J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153:420–421CrossRefPubMed

Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322CrossRefPubMedPubMedCentral

10.

Vitiello A, La Porta R, D’Aiuto V, Ferrara F (2021) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https://doi.org/10.1016/j.humimm.2021.01.007CrossRefPubMedPubMedCentral

11.

Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R (2020) Cytokine storm and colchicine potential role in fighting SARS-CoV‑2 pneumonia. Ital J Med 14(2):88–94

12.

Ferrara F, Porta R, D’Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02401-5CrossRefPubMedPubMedCentral

13.

Jorgensen SCJ, Kebriaei R, Dresser LD (2020) Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40(7):659–671. https://doi.org/10.1002/phar.2429CrossRefPubMedPubMedCentral

14.

Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02440-yCrossRefPubMedPubMedCentral

15.

Vitiello A, La Porta R, Ferrara F (2020) Sacubitril, valsartan and SARS-CoV‑2. BMJ Evid Based Med. https://doi.org/10.1136/bmjebm-2020-111497CrossRefPubMed

16.

Vitiello A, La Porta R, Trama U, Ferrara F, Zovi A, Auti AM, Di Domenico M, Boccellino M (2022) Pandemic COVID-19, an update of current status and new therapeutic strategies. Naunyn Schmiedebergs Arch Pharmacol. https://doi.org/10.1007/s00210-022-02265-9CrossRefPubMed

17.

Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-coV‑2 : anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 76(11):1615–1618. https://doi.org/10.1007/s00228-020-02947-4CrossRefPubMedPubMedCentral

18.

Vitiello A, Pelliccia C, Ferrara F (2021) Drugs acting on the renin-angiotensin system and SARS-CoV‑2. Drug Discov Today 26(4):870–874. https://doi.org/10.1016/j.drudis.2021.01.010CrossRefPubMedPubMedCentral

19.

Vitiello A, Ferrara F (2021) Therapeutic strategies for SARS-CoV‑2 acting on ACE‑2. Eur J Pharm Sci 156:105579. https://doi.org/10.1016/j.ejps.2020.105579CrossRefPubMed

20.

Gurwitz D (2020) Angiotensin receptor blockers as tentative SARSCoV‑2 therapeutics. Drug Dev Res 81:537–540CrossRefPubMedPubMedCentral

21.

Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H (2004) Tissue distribution of ACE‑2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–637CrossRefPubMedPubMedCentral

22.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE-2) as a SARS-CoV‑2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586–590CrossRefPubMedPubMedCentral

23.

Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M et al (2012) ACE‑2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487(7408):477–481CrossRefPubMedPubMedCentral

24.

Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS (2003) The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 312:1159–1164CrossRefPubMedPubMedCentral

25.

Li F, Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864–1868CrossRefPubMed

26.

Verdecchia P, Reboldi G, Cavallini C, Mazzotta G, Angeli F (2020) ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus. G Ital Cardiol 21(5):321–327. https://doi.org/10.1714/3343.331227CrossRef

27.

Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322CrossRefPubMedPubMedCentral

28.

Satou R, Penrose H, Navar G (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep. https://doi.org/10.1007/s11906-018-0900-0CrossRefPubMedPubMedCentral

29.

Ferrara F, Vitiello A (2020) Potential pharmacological approach in the regulation of ACE‑2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. https://doi.org/10.4081/itjm.2020.1435CrossRef

30.

Vitiello A, La Porta R, Ferrara F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 147:110486. https://doi.org/10.1016/j.mehy.2021.110486CrossRefPubMedPubMedCentral

31.

Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S (2020) Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol 17(2):116–129. https://doi.org/10.1038/s41569-019-0244-8CrossRefPubMed

32.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382(17):1653–1659. https://doi.org/10.1056/NEJMsr2005760CrossRefPubMed

33.

Vitiello A, Ferrara F (2020) Correlation between renin-angiotensin system and severe acute respiratory syndrome Coronavirus 2 infection: what do we know? Eur J Pharmacol 883:173373. https://doi.org/10.1016/j.ejphar.2020.173373CrossRefPubMedPubMedCentral

34.

Vitiello A, Ferrara F (2020) Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 262:118510. https://doi.org/10.1016/j.lfs.2020.118510CrossRefPubMedPubMedCentral

35.

Imai Y, Kuba K, Penninger JM (2007) Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 64(15):2006–2012CrossRefPubMedPubMedCentral

36.

Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, Mustafa G (2020) Treatment options available for COVID-19 and an analysis on possible role of combination of rhACE‑2, angiotensin (1–7) and angiotensin (1–9) as effective therapeutic measure. SN Compr Clin Med. https://doi.org/10.1007/s42399-020-00407-9CrossRefPubMedPubMedCentral

37.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV‑2 infections in engineered human tissues using clinical-grade soluble human ACE‑2. Cell 181(4):905–913.e7. https://doi.org/10.1016/j.cell.2020.04.004CrossRefPubMedPubMedCentral

38.

Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, Zhang H, Slutsky AS, Hurtado Del Pozo C, Horn M, Montserrat N, Penninger JM, Mirazimi A (2021) Human soluble ACE‑2 improves the effect of remdesivir in SARS-CoV‑2 infection. EMBO Mol Med 13(1):e13426. https://doi.org/10.15252/emmm.202013426CrossRefPubMed

39.

Vitiello A, Ferrara F, La Porta R (2021) Remdesivir and COVID-19 disease, therapeutic benefitsor unnecessary risks? Ir J Med Sci 190(4):1637–1638CrossRefPubMedPubMedCentral

40.

Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N, Landry DW, Giustina A (2020) Mechanisms in endocrinology: vitamin D and COVID-19. Eur J Endocrinol 183(5):R133–R147. https://doi.org/10.1530/EJE-20-0665CrossRefPubMedPubMedCentral

41.

Marquez A, Wysocki J, Pandit J, Batlle D (2021) An update on ACE‑2 amplification and its therapeutic potential. Acta Physiol (Oxf) 231(1):e13513. https://doi.org/10.1111/apha.13513CrossRefPubMed

42.

Dutta K (2022) Allosteric site of ACE‑2 as a drug target for COVID-19. ACS Pharmacol Transl Sci 5:179–182CrossRefPubMedPubMedCentral

43.

Huang L, Chen Z, Ni L, Chen L, Zhou C, Gao C, Wu X, Hua L, Huang X, Cui X et al (2021) Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the inflammatory response and viral clearance in COVID-19 patients. Front Cardiovasc Med 8:710946CrossRefPubMedPubMedCentral

Titel: Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions
verfasst von: Antonio Vitiello, MD
Andrea Zovi, PD
Ugo Trama, MD
Francesco Ferrara, MD
Publikationsdatum: 04.11.2022
Verlag: Springer Medizin
Schlagwort: COVID-19
Erschienen in: Herz / Ausgabe 5/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-022-05142-6

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions

Abstract

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

Intervallfasten zur Regeneration des Herzmuskels?

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Bildgebende Diagnostik der kardialen Sarkoidose

Comparison of outcomes between single long stent and overlapping stents: a meta-analysis of the literature

Kardiovaskuläre Therapie bei chronischer Nierenerkrankung

Koronare CT-Angiographie und koronare Atherosklerose

Echokardiographie mit hohen Bildraten in der klinischen Praxis

Computed tomography to guide transcatheter aortic valve implantation

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

Intervallfasten zur Regeneration des Herzmuskels?

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Kardiologie